# Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma

> **NCT02677597** · PHASE3 · UNKNOWN · sponsor: **Fudan University** · enrollment: 268 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Cisplatin Combined With S-1
- **DRUG:** Cisplatin Combined With Paclitaxel

## Key facts

- **NCT ID:** NCT02677597
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2019-01
- **Final completion:** 2019-01
- **Target enrollment:** 268 (ESTIMATED)
- **Last updated:** 2016-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02677597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02677597, "Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02677597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*